Jonathan Wang

Jonathan Wang is a prominent figure in the biopharmaceutical industry with extensive experience in healthcare and life sciences. He is the Founder, Chairman, and CEO of Inmagene Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel therapies for immunology-related diseases.12

Education and Early Career

Dr. Wang holds impressive academic credentials:

• Ph.D. in Neurobiology from Columbia University, where he was awarded the Howard Hughes Medical Institute (HHMI) Research Fellowship under the supervision of Nobel Laureate Eric Kandel1
• MBA from Stanford University Graduate School of Business12

Professional Experience

Dr. Wang's career spans over 30 years, encompassing various roles:

• Founder, Chairman, and CEO of Inmagene Biopharmaceuticals (2019-present)2
• Partner at OrbiMed, a leading healthcare-dedicated investment firm, where he co-founded OrbiMed Asia and led the establishment of $1.1B PE/VE funds1
• Board Member and Former Chairman at Apollomics2
• Managing Director at WI Harper Group (2001)2

Achievements at Inmagene Biopharmaceuticals

Under Dr. Wang's leadership, Inmagene has:

• Raised approximately $140 million in financing1
• Developed a strong pipeline with over 10 drug candidates1
• Established wholly owned subsidiaries in San Diego, Shanghai, Hangzhou, and Wuhan1
• Advanced its lead drug candidate, IMG-020, to global phase 2 or 3 trials for 5 autoimmune indications1

Recognition and Contributions

Dr. Wang has been recognized for his contributions to the healthcare industry:

• Named one of the top 10 healthcare investors in China1
• Serves as a HKEX Biotech Advisory Panel member1
• Co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders1

Additionally, Dr. Wang has authored two philosophy of science books, further demonstrating his expertise and thought leadership in the field.1